Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial

Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist approved for the treatment of acute migraine headaches. Ubrogepant demonstrated efficacy and safety in 2 pivotal phase 3 studies (N = 2240) that led to its approval. Here, we report the pharmacokinetics and safety results from...

Descripción completa

Detalles Bibliográficos
Autores principales: Boinpally, Ramesh, Lu, Kaifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306593/
https://www.ncbi.nlm.nih.gov/pubmed/35174666
http://dx.doi.org/10.1002/cpdd.1066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306593/
https://www.ncbi.nlm.nih.gov/pubmed/35174666
http://dx.doi.org/10.1002/cpdd.1066

Ejemplares similares